IMDELLTRA® Patient Videos for Extensive Stage Small Cell Lung Cancer

00:00–00:17

Narrator: Brian is living with extensive stage small cell lung cancer. He completed platinum-based chemotherapy and initially experienced an
improvement in his disease. However, his recent scans show that his cancer has relapsed and is growing again.

00:18–00:25

Narrator: Brian and his doctor are discussing what the scan findings mean for Brian’s treatment journey.

00:26–00:39

Doctor: I know hearing about your cancer growing after your first-line treatment is tough. Whatever you're feeling, it's all valid.

Patient: (Looking sad and scared) I'm frustrated. I just need to know if there are still treatment options for me, or if chemo was the only choice?

00:40–01:10

Doctor: There are other options in the second-line setting, one of which is called IMDELLTRA^®—also known as tarlatamab. It works differently in
your body from the chemo you’ve tried, and it’s approved by the FDA for adults with extensive stage small cell lung cancer who have received
treatment with chemotherapy that contains platinum, and it did not work or is no longer working. Extensive stage is cancer that has
spread throughout the lung or to other parts of the body.

01:11–02:44

Narrator: What is IMDELLTRA^®, or tarlatamab-dlle?

IMDELLTRA^® is a prescription medicine used to treat adults with extensive stage small cell lung cancer (ES-SCLC), which is cancer that has
spread throughout the lung or to other parts of the body, and who have received treatment with chemotherapy that contains platinum, and it did
not work or is no longer working. It is not known if IMDELLTRA^® is safe and effective in children.

Important Safety Information

What is the most important information I should know about IMDELLTRA^®?

IMDELLTRA^® can cause side effects that can be severe, life-threatening or cause death, including:

Cytokine Release Syndrome (CRS). CRS is common during treatment with IMDELLTRA^® and can be severe, life-threatening, or cause death. Tell
your healthcare provider or get medical help right away if you develop any signs or symptoms of CRS, including:

Fever of 100.4°F, or 38°C, or higher

Low blood pressure

Tiredness

Fast heartbeat or dizziness

Headache

Shortness of breath or trouble breathing

Nausea and vomiting

Confusion, restlessness, or feeling anxious

Problems with balance and movement, such as trouble walking

Heart, liver, or kidney problems

Blood clots or unusual bleeding or bleeding that lasts a long time

02:45–04:54

Narrator: Important Safety Information (continued).

Due to the risk of CRS, you will receive IMDELLTRA^® as per the following “step-up dosing schedule”:

The step-up dosing schedule is when you receive a smaller dose of IMDELLTRA^® on Day 1 of your first treatment cycle (Cycle 1).

You will receive the full treatment dose of IMDELLTRA^® on Day 8 and Day 15 of Cycle 1. You will receive the full treatment dose 1 time every
2 weeks after Day 15 of Cycle 1. If your dose of IMDELLTRA^® is delayed for any reason, you may need to repeat the “step-up dosing schedule”.
Before receiving your Day 1 and Day 8 doses of Cycle 1 of IMDELLTRA^®, you will be given a medicine to help reduce your risk of CRS. This will be
given into your vein by intravenous (IV) infusion. You will also receive IV fluids after each of your Cycle 1 Day 1 and Day 8 doses. Your healthcare provider will decide if you need to receive medicines to help reduce your risk of CRS with future doses.

Neurologic Problems. IMDELLTRA^® can cause neurologic problems that can be severe, life-threatening, or cause death. Neurologic problems may
happen days or weeks after you receive IMDELLTRA^®. Your healthcare provider may refer you to a healthcare provider who specializes in
neurologic problems. Tell your healthcare provider right away if you develop any signs or symptoms of neurologic problems, including:

Changes in taste

Headache

Numbness or tingling of your hands or feet

Dizziness

Trouble sleeping

Muscle weakness or numbness of arms or legs

Problems with walking, or loss of balance or coordination

Trouble speaking, memory loss, or personality changes

Confusion, feeling disoriented, slow thinking, or not being able to think clearly

Fainting or loss of consciousness

Seizures

Shaking or tremors

Sleepiness

Feeling like you have no energy

04:55–06:37

Narrator: Important Safety Information (continued).

Due to the risk of CRS and neurologic problems, you will receive the following monitoring during treatment with IMDELLTRA^®:

For Day 1 and Day 8 of Cycle 1 doses, your healthcare provider will monitor you for 22 to 24 hours from the start of the IMDELLTRA^® infusion in a healthcare setting that can manage these side effects.

You should remain within 1 hour of a healthcare setting for a total of 48 hours from the start of the IMDELLTRA^® infusion after your Day 1 and Day 8 of Cycle 1 doses and be accompanied by a caregiver.

For Day 15 of Cycle 1 and Cycle 2 doses, your healthcare provider will watch you for 6 to 8 hours after the IMDELLTRA^® infusion.

For Cycle 3 and Cycle 4 doses, your healthcare provider will watch you for 3 to 4 hours after the IMDELLTRA^® infusion.

For Cycle 5 and later doses, your healthcare provider will watch you for 2 hours after the IMDELLTRA^® infusion.

Your healthcare provider will monitor you for signs and symptoms of CRS and neurologic problems during treatment with IMDELLTRA^® and treat
you as needed. You may be hospitalized if you develop signs or symptoms of CRS or neurologic problems during treatment with IMDELLTRA^®.
Your healthcare provider may temporarily stop or completely stop your treatment with IMDELLTRA^® if you develop CRS or neurologic problems.

Please see additional important safety information at the end of this video and full Prescribing Information, including BOXED WARNINGS and Medication Guide on IMDELLTRA.com.

06:38–08:18

Patient: So, it’s not another type of chemo?

Doctor: No, it’s not chemotherapy. Instead, it's designed to use your body's own immune system to target and to help fight small cell lung cancer
cells.

Patient: How would I receive IMDELLTRA^®?

Doctor: Well, IMDELLTRA^® will be given by a healthcare provider in a hospital or clinic setting by intravenous infusion over 1 hour, which means
the medicine goes into your body through a needle placed in a vein.

Your IMDELLTRA^® treatment schedule is divided into cycles that are usually 28 days or 4 weeks long.

Patient: And how often will I have to come in for infusions?

Doctor: You will receive treatment using a step-up dosing schedule, which means we will start with a smaller dose and carefully monitor how you
respond on Day 1 of your first treatment cycle. Then, you will receive the full treatment dose on Day 8 and Day 15 of Cycle 1. After that, you will
receive additional doses every 2 weeks until your disease progresses or you are unable to tolerate the side effects. (Doctor pauses to give patient
a chance to comment)

Patient: Ok.

Doctor: Before receiving the first 2 doses of IMDELLTRA^® on Cycle 1 Day 1 and Day 8, you will be given a medicine also by intravenous infusion to
help reduce your risk of cytokine release syndrome, or CRS.

You will also receive IV fluids after each of your Cycle 1 Day 1 and Day 8 doses. As your doctor, I will decide if you need to receive medicines to
help reduce your risk of CRS with future doses and how many treatment cycles you will need to receive.

08:19–08:27

Patient: I see…(thinking)…But has it been shown to work in patients?

Doctor: Let me share some information on IMDELLTRA^® with you.

08:28–09:04

Doctor: In a study of 509 people with extensive stage small cell lung cancer whose cancer worsened after receiving treatment with
chemotherapy containing platinum, 254 people were randomly assigned to receive IMDELLTRA^® and 255 people were assigned to receive
chemotherapy. Half of the people who were treated with IMDELLTRA^® were alive at 13.6 months.

For those treated with chemotherapy, half were alive at 8.3 months.

Patient: (Visibly hopeful) So, living longer is possible with IMDELLTRA^®...

(THOUGHTFULLY OUT LOUD) And that could mean more time...

09:05–09:17

Patient: For me, more time means I might actually be able to welcome my first grandkid.

But what does being on IMDELLTRA^® look like? What side effects should I expect?

09:18–10:31

Doctor: IMDELLTRA^® can cause side effects that can be serious, life-threatening, or lead to death, including CRS and neurologic problems.

I will monitor you for signs and symptoms of CRS and neurologic problems during treatment with IMDELLTRA^® and treat you as needed. You may
be hospitalized if you develop signs or symptoms of CRS or neurologic problems during treatment with IMDELLTRA^®, and I may temporarily stop
or completely stop your treatment with IMDELLTRA^® if you develop CRS or neurologic problems.

Other side effects may include low blood cell counts, infections, liver problems, allergic reactions, tiredness, fever, a bad or metallic taste in your
mouth, decreased appetite, constipation, nausea, headache, anemia, and muscle or bone pain. Still, these are not all the possible side effects
of IMDELLTRA^®.

Patient: Life-threatening or cause death? That’s hard to hear.

Doctor: I understand your concern. Please know that we will monitor you carefully for side effects during treatment and manage them as
appropriate, which may involve hospitalization.

Patient: Seems like “more time” means “more time in the hospital.”

10:32–12:24

Doctor: Well, it depends on your response to IMDELLTRA^®. Due to the risk of CRS and neurologic problems, I will monitor you during your
treatment with IMDELLTRA^®. For the first 2 doses on Day 1 and Day 8 of Cycle 1, we will monitor you for 22 to 24 hours from the start of your
IMDELLTRA^® infusion in a healthcare setting that can manage potential side effects.

Patient: (Nodding tentatively) Ok.

Doctor: Do you have someone—a family member or friend—who could help you during IMDELLTRA^® treatment? I believe I met your son and your
wife at previous appointments.

Patient: That's right. They both helped out during chemo.

Doctor: Great. You’ll want to rely on them again. You and your caregiver will need to stay within 1 hour of our care center for 48 hours from the
start of the IMDELLTRA^® infusion after your Day 1 and Day 8 of Cycle 1 doses, but you may be able to go home afterwards depending on your
response to treatment.

For the next 3 doses—the infusions on Day 15 of Cycle 1 and Days 1 and 15 of Cycle 2—we will monitor you for 6 to 8 hours after each infusion. And
then for the next 4 doses, we will plan to monitor you for 3 to 4 hours after infusion. And for subsequent doses, we'll monitor you for 2 hours after
each infusion.

Patient: So, the monitoring time starts out at 22 to 24 hours after infusion but ultimately goes down to 2 hours?

Doctor: That's right. We prioritize monitoring because we are always keeping in mind your safety.

As your doctor, I will continue to monitor you for signs and symptoms of CRS and neurologic problems during all doses of your treatment with
IMDELLTRA^® and treat you as needed. You may be hospitalized if you develop signs or symptoms of CRS or neurologic problems during your
treatment with IMDELLTRA^®.

12:25–12:27

Patient: So, are long hospital stays required with IMDELLTRA^®?

12:28–12:57

Doctor: We'll decide together based on how you respond to treatment. And, one of the ways we watch for this response is by using a step-up
dosing approach, which means you will receive a smaller dose of treatment first before receiving the full dose. This is to reduce the risk of CRS.

Doctor: Before you go home, we'll inform you and your caregiver on the signs and symptoms of CRS and neurologic problems, so you know what
to watch for.

Patient: Thank you, that’s reassuring to hear.

12:58–13:07

HCP: I’m glad.

Patient: I do want more time for more of life’s little moments…

(Smiling looking off pensively) …meals with my family, watching ball games with my son.

13:08–13:25

Doctor: I understand.

If you do choose IMDELLTRA^® as your next step, know that you won’t be alone on the journey. You can count on my team for all the information
you need, and there are patient navigators and support groups to help you along the way.

13:26–13:33

Patient: Then let’s do it.

I'm ready to try IMDELLTRA^®...for the chance of more time with the people I love.

13:34–15:10

Narrator: What is IMDELLTRA^®, or tarlatamab-dlle?

It is not known if IMDELLTRA^® is safe and effective in children.

Important Safety Information

What is the most important information I should know about IMDELLTRA^®?

IMDELLTRA^® can cause side effects that can be severe, life-threatening or cause death, including:

Fever of 100.4°F, or 38°C, or higher

Low blood pressure

Tiredness

Fast heartbeat or dizziness

Headache

Shortness of breath or trouble breathing

Nausea and vomiting

Confusion, restlessness, or feeling anxious

Problems with balance and movement, such as trouble walking

Heart, liver, or kidney problems

Blood clots or unusual bleeding or bleeding that lasts a long time

15:11–17:18

Narrator: Important Safety Information (continued).

Due to the risk of CRS, you will receive IMDELLTRA^® as per the following “step-up dosing schedule”:

The step-up dosing schedule is when you receive a smaller dose of IMDELLTRA^® on Day 1 of your first treatment cycle (Cycle 1).

Before receiving your Day 1 and Day 8 doses of Cycle 1 of IMDELLTRA^®, you will be given a medicine to help reduce your risk of CRS. This will be
given into your vein by intravenous (IV) infusion. You will also receive IV fluids after each of your Cycle 1 Day 1 and Day 8 doses. Your healthcare
provider will decide if you need to receive medicines to help reduce your risk of CRS with future doses.

Changes in taste

Headache

Numbness or tingling of your hands or feet

Dizziness

Trouble sleeping

Muscle weakness or numbness of arms or legs

Problems with walking, or loss of balance or coordination

Trouble speaking, memory loss, or personality changes

Confusion, feeling disoriented, slow thinking, or not being able to think clearly

Fainting or loss of consciousness

Seizures

Shaking or tremors

Sleepiness

Feeling like you have no energy

17:19–18:50

Narrator: Important Safety Information (continued).

Due to the risk of CRS and neurologic problems, you will receive the following monitoring during treatment with IMDELLTRA^®:

For Day 1 and Day 8 of Cycle 1 doses, your healthcare provider will monitor you for 22 to 24 hours from the start of the IMDELLTRA^® infusion in a
healthcare setting that can manage these side effects.

You should remain within 1 hour of a healthcare setting for a total of 48 hours from the start of the IMDELLTRA^® infusion after your Day 1 and Day
8 of Cycle 1 doses and be accompanied by a caregiver.

For Day 15 of Cycle 1 and Cycle 2 doses, your healthcare provider will watch you for 6 to 8 hours after the IMDELLTRA^® infusion.

For Cycle 3 and Cycle 4 doses, your healthcare provider will watch you for 3 to 4 hours after the IMDELLTRA^® infusion.

For Cycle 5 and later doses, your healthcare provider will watch you for 2 hours after the IMDELLTRA^® infusion.

18:51–20:23

Narrator: Important Safety Information (continued).

Before receiving IMDELLTRA^®, tell your healthcare provider about all of your medical conditions, including if you:

Have an infection

Are pregnant or plan to become pregnant. IMDELLTRA^® may harm your unborn baby.

Females who are able to become pregnant:

Your healthcare provider should do a pregnancy test before you start treatment with IMDELLTRA^®.

You should use an effective form of birth control (contraception) during treatment with IMDELLTRA^®, and for 2 months after the last dose of
IMDELLTRA^®.

Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with IMDELLTRA^®.
Are breastfeeding or plan to breastfeed. It is not known if IMDELLTRA^® passes into your breast milk. Do not breastfeed during treatment with
IMDELLTRA^® and for 2 months after the last dose of IMDELLTRA^®.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal
supplements.

What should I avoid while receiving IMDELLTRA^®?

Do not drive, operate heavy or potentially dangerous machinery or do other dangerous activities, including work-related activities, during
treatment with IMDELLTRA^® if you develop dizziness, confusion, tremors, sleepiness, or any other symptoms that impair consciousness until your
signs and symptoms go away. These may be signs and symptoms of neurologic problems.

20:24–22:15

Narrator: Important Safety Information (continued).

What are the possible side effects of IMDELLTRA^®?

IMDELLTRA^® can cause serious side effects, including:

Low white blood cell counts (cytopenia). Decreased blood cell counts can be severe and may include the following:

Low types of white blood cell counts (neutropenia). Low white blood cells can increase your risk for infection.

Low red blood cell counts (anemia). Low red blood cells can cause tiredness and shortness of breath.

Low platelet counts (thrombocytopenia). Low platelet counts can cause bruising or bleeding problems.

Infections. IMDELLTRA^® can cause serious infections that can be life-threatening and cause death. Your healthcare provider will check you for
signs and symptoms of infection before and during treatment with IMDELLTRA^®. Tell your healthcare provider right away if you develop any signs
or symptoms of infection during treatment with IMDELLTRA^®, including: fever of 100.4°F, or 38°C, or higher; painful rash, cough, sore throat or
runny nose, chest pain, pain during urination, tiredness, feeling weak or generally unwell, shortness of breath, yeast infections in the mouth or
other areas.

Liver problems. IMDELLTRA^® can cause increased liver enzymes and bilirubin in your blood. These increases can happen with or without you also
having CRS. Tell your healthcare provider right away if you develop any signs or symptoms of liver problems, including: tiredness, dark urine, loss
of appetite, yellowing of your skin or the white part of your eyes, pain in your right upper stomach-area (abdomen).

22:16–23:46

Narrator: Important Safety Information (continued).

IMDELLTRA^® can cause serious side effects, including (continued):

Allergic reactions. IMDELLTRA^® can cause allergic reactions that can be severe. Go to the nearest emergency room or get medical help right
away if you develop any signs or symptoms of a severe allergic reaction during treatment with IMDELLTRA^®, including: shortness of breath or
trouble breathing, coughing, pain or tightness in your chest and back, feeling lightheaded or dizzy, wheezing, rash.

Your healthcare provider will do bloodwork before you start and during treatment with IMDELLTRA^®. Your healthcare provider will monitor you
for signs or symptoms of these serious side effects during treatment and may temporarily or completely stop treatment with IMDELLTRA^® if you
develop certain serious side effects.

The most common side effects of IMDELLTRA^® also include:

Tiredness

Decreased appetite

A bad or metallic taste in your mouth

Fever

Muscle or bone pain

Constipation

Nausea

These are not all the possible side effects of IMDELLTRA^®.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see IMDELLTRA^® full Prescribing Information, including BOXED WARNINGS and Medication Guide on IMDELLTRA.com.

0:00–00:18

Narrator: Barbara has extensive stage small cell lung cancer and has been undergoing treatment with chemotherapy containing platinum. Her
recent scans show that her cancer is not responding to treatment. Barbara and her daughter are disappointed that the chemotherapy is not
working.

00:19–00:25

Narrator: They are meeting with the oncologist to discuss what this means for Barbara’s treatment journey.

00:26–01:02

Doctor: I know that receiving news about your cancer not responding to treatment can be overwhelming and may make you feel uncertain about
the future. That's completely understandable.

Patient: I'm just...I'm tired. I don't know if I have the energy for another round.

Caregiver (Daughter): Mom, I know you're exhausted. I understand. We don’t have to make any decisions right now, but maybe hearing our
options will help us figure out our next step?

Doctor: (Turns to patient) Let me ask you this. What's most important to you right now in terms of your care?

01:03–01:19

Patient: I'm not sure...I don't know what to hope for at this point...(hesitates and thinks)...I just wish something more could be done.

Doctor: I’d like to share information about a treatment option, IMDELLTRA^®—also known as tarlatamab.

01:20–02:50

Narrator: What is IMDELLTRA^®, or tarlatamab-dlle?

It is not known if IMDELLTRA^® is safe and effective in children.

Important Safety Information

What is the most important information I should know about IMDELLTRA^®?

IMDELLTRA^® can cause side effects that can be severe, life-threatening or cause death, including:

Fever of 100.4°F, or 38°C, or higher

Low blood pressure

Tiredness

Fast heartbeat or dizziness

Headache

Shortness of breath or trouble breathing

Nausea and vomiting

Confusion, restlessness, or feeling anxious

Problems with balance and movement, such as trouble walking

Heart, liver, or kidney problems

Blood clots or unusual bleeding or bleeding that lasts a long time

02:51–04:58

Narrator: Important Safety Information (continued).

Due to the risk of CRS, you will receive IMDELLTRA^® as per the following “step-up dosing schedule”:

The step-up dosing schedule is when you receive a smaller dose of IMDELLTRA^® on Day 1 of your first treatment cycle (Cycle 1).

You will receive the full treatment dose of IMDELLTRA^® on Day 8 and Day 15 of Cycle 1. You will receive the full treatment dose 1 time every
2 weeks after Day 15 of Cycle 1. If your dose of IMDELLTRA^® is delayed for any reason, you may need to repeat the “step-up dosing schedule”.
Before receiving your Day 1 and Day 8 doses of Cycle 1 of IMDELLTRA^®, you will be given a medicine to help reduce your risk of CRS. This will be
given into your vein by intravenous (IV) infusion. You will also receive IV fluids after each of your Cycle 1 Day 1 and Day 8 doses. Your healthcare
provider will decide if you need to receive medicines to help reduce your risk of CRS with future doses.

Changes in taste

Headache

Numbness or tingling of your hands or feet

Dizziness

Trouble sleeping

Muscle weakness or numbness of arms or legs

Problems with walking, or loss of balance or coordination

Trouble speaking, memory loss, or personality changes

Confusion, feeling disoriented, slow thinking, or not being able to think clearly

Fainting or loss of consciousness

Seizures

Shaking or tremors

Sleepiness

Feeling like you have no energy

04:59–06:39

Narrator: Important Safety Information (continued).

Due to the risk of CRS and neurologic problems, you will receive the following monitoring during treatment with IMDELLTRA^®:

For Day 1 and Day 8 of Cycle 1 doses, your healthcare provider will monitor you for 22 to 24 hours from the start of the IMDELLTRA^® infusion in a
healthcare setting that can manage these side effects.

You should remain within 1 hour of a healthcare setting for a total of 48 hours from the start of the IMDELLTRA^® infusion after your Day 1 and Day
8 of Cycle 1 doses and be accompanied by a caregiver.

For Day 15 of Cycle 1 and Cycle 2 doses, your healthcare provider will watch you for 6 to 8 hours after the IMDELLTRA^® infusion.

For Cycle 3 and Cycle 4 doses, your healthcare provider will watch you for 3 to 4 hours after the IMDELLTRA^® infusion.

For Cycle 5 and later doses, your healthcare provider will watch you for 2 hours after the IMDELLTRA^® infusion.

Your healthcare provider will monitor you for signs and symptoms of CRS and neurologic problems during treatment with IMDELLTRA^®
and treat you as needed. You may be hospitalized if you develop signs or symptoms of CRS or neurologic problems during treatment with IMDELLTRA^®.
Your healthcare provider may temporarily stop or completely stop your treatment with IMDELLTRA^® if you develop CRS or neurologic problems.

Please see additional important safety information at the end of this video and full Prescribing Information, including BOXED WARNINGS and
Medication Guide on IMDELLTRA.com.

06:40–07:35

Doctor: IMDELLTRA^® is a type of targeted immunotherapy called a T-cell engager, and it’s approved by the FDA for adults with extensive stage
small cell lung cancer who have received treatment with chemotherapy that contains platinum, and it did not work or is no longer working.
Extensive stage is cancer that has spread throughout the lung or to other parts of the body.

Caregiver: How is it different from what my mom has been through already?

Doctor: IMDELLTRA^® is not chemotherapy. It uses your body's own immune system to target and help fight small cell lung cancer cells by
recognizing specific molecules on their surface.

Patient: It’s interesting that it helps the immune system find and destroy small cell lung cancer cells. But tell me more, how is it given? Would I
need to go into the hospital?

07:36–08:26

Doctor: So, IMDELLTRA^® is given as an intravenous infusion by your doctor, which means the medicine goes into your body through a needle
placed in a vein, for an hour each time, in a hospital or clinic setting.

To reduce the risk of cytokine release syndrome, or CRS, which is common during treatment with IMDELLTRA^®, you'll receive treatment using a
step-up dosing schedule, which means we will start with a smaller dose and carefully monitor how you respond on Day 1 of your first treatment
cycle. Then, you’ll receive the full treatment dose on Day 8 and Day 15 of Cycle 1.

After that, you’ll receive additional doses 1 time every 2 weeks until your disease progresses or you are unable to tolerate the side effects.

(Doctor pauses to give the patient and caregiver a chance to comment)

08:27–09:06

Patient: So, infusions every other week?

Doctor: Yes, after the doses on Days 1, 8, and 15 of Cycle 1, you will receive infusions every other week.

To help reduce your risk of CRS, before receiving the first 2 doses of IMDELLTRA^®, you will be given a medicine, also by intravenous infusion.

For future doses, I will decide if more medicines are needed. Your IMDELLTRA^® treatment schedule is divided into cycles that are usually 28 days
or 4 weeks long.

As your doctor, I will decide how many treatment cycles you will need to receive.

09:07–11:07

Patient: When you say “monitor,” does that mean I'll be staying in the hospital for a long time?

Doctor: Well, it depends on your response to IMDELLTRA^®. Due to the risk of CRS and neurologic problems, I will monitor you during your
treatment with IMDELLTRA^®. For the first 2 doses, we will monitor you for 22 to 24 hours from the start of the infusion in a healthcare setting. We
will need you and your caregiver, your daughter in this case, to stay within 1 hour of our care center for 48 hours after each of the first two doses.

For the next 3 doses—the IMDELLTRA^® infusions on Day 15 of Cycle 1 and Days 1 and 15 of Cycle 2—we will watch you for 6 to 8 hours after each
infusion. And for the 4 infusions after that–the infusions in Cycle 3 and Cycle 4–we will watch you for 3 to 4 hours after each infusion.

Patient: Oh, I see.

Doctor: We will monitor you for side effects and treat you as needed. Once we get to Cycle 5, and for subsequent doses, we will watch you for
2 hours after each infusion. So, you will always receive some monitoring after infusion.

Patient: OK, and just to be sure I understand, because I live over an hour away, after those first 2 doses where you want us to stay close to the
care center for 48 hours, for any subsequent doses I would be able to go home after the infusion and monitoring time are completed?

Doctor: That's right. If our monitoring of your signs and symptoms indicates that it is appropriate to do so, you will be able to go home. Before she leaves the hospital, we’ll inform you both on the signs and symptoms of CRS and neurologic problems that may occur with
IMDELLTRA^®.

I'm glad your daughter is here with you because she will play an important role in your treatment with IMDELLTRA^®.

11:08–11:25

Caregiver: So, would my mom have a long stay in the hospital?

Doctor: We would need to see how she responds to the first two doses. Before she leaves the hospital, we’ll inform you both on the signs and
symptoms of CRS and neurologic problems that may occur with IMDELLTRA^®.

11:26–13:06

Patient: I’d be interested in moving forward, but I need to understand more about side effects and treatment logistics. I don't like the idea of my
daughter having to constantly look after me.

Caregiver: It’s ok, mom. We’ll handle this together. I agree though; we need to know what’s involved.

Doctor: That’s fair. IMDELLTRA^® can cause side effects that can be serious, life-threatening, or cause death, including CRS and neurologic
problems. We will monitor for side effects and treat you as needed.

You may be hospitalized if you develop signs or symptoms of CRS or neurologic problems during treatment with IMDELLTRA^®, and I may
temporarily stop or completely stop your treatment with IMDELLTRA^® if you develop CRS or neurologic problems.

Patient: Ok.

Doctor: Other side effects may include low blood cell counts, infections, liver problems, allergic reactions, tiredness, fever, a bad or metallic taste
in your mouth, decreased appetite, constipation, nausea, headache, anemia, and muscle or bone pain. Still, these are not all the possible side
effects of IMDELLTRA^®.

After the first 2 doses, before you are discharged, we’d inform you both of the signs and symptoms of CRS and neurologic problems to watch for,
and provide you with a wallet card that has our direct contact information, in case you have any questions.

13:07–13:15

Patient: This sounds like a lot to coordinate. I’m worried about being a burden, especially to my daughter…

13:16–13:20

Caregiver: (Turns to mom sincerely) Mom, I want to help.

(Turns to doctor) Will there be someone to help guide us through everything?

13:21–13:38

Doctor: Yes. If you begin treatment with IMDELLTRA^®, there are Patient Navigators, individuals who aren't members of your care team, but who
can help guide you through the treatment logistics and can connect you with support groups where you can engage with other patients and
caregivers.

13:39–13:41

Caregiver: What would my role be? How can I best support my mom?

13:42–13:56

Doctor: Your support is invaluable. We’ll provide educational materials and direct access to the care team. You're not expected to be a medical
expert; just be the loving daughter you already are and support your mom in her treatment journey.

13:57–14:03

Patient: Who knows what the future holds...(PAUSE/LOOK AT DAUGHTER)

(LOOK BACK AT DOCTOR)…but I’m ready to try IMDELLTRA^®.

14:04–14:14

Doctor: That's great. I'll get you connected with the resources you need.

I think IMDELLTRA^® could be a good option for you.

14:15–15:45

Narrator: What is IMDELLTRA^®, or tarlatamab-dlle?

It is not known if IMDELLTRA^® is safe and effective in children.

Important Safety Information

What is the most important information I should know about IMDELLTRA^®?

IMDELLTRA^® can cause side effects that can be severe, life-threatening or cause death, including:

Fever of 100.4°F, or 38°C, or higher

Low blood pressure

Tiredness

Fast heartbeat or dizziness

Headache

Shortness of breath or trouble breathing

Nausea and vomiting

Confusion, restlessness, or feeling anxious

Problems with balance and movement, such as trouble walking

Heart, liver, or kidney problems

Blood clots or unusual bleeding or bleeding that lasts a long time

15:46–17:52

Narrator: Important Safety Information (continued).

Due to the risk of CRS, you will receive IMDELLTRA^® as per the following “step-up dosing schedule”:

The step-up dosing schedule is when you receive a smaller dose of IMDELLTRA^® on Day 1 of your first treatment cycle (Cycle 1).

Changes in taste

Headache

Numbness or tingling of your hands or feet

Dizziness

Trouble sleeping

Muscle weakness or numbness of arms or legs

Problems with walking, or loss of balance or coordination

Trouble speaking, memory loss, or personality changes

Confusion, feeling disoriented, slow thinking, or not being able to think clearly

Fainting or loss of consciousness

Seizures

Shaking or tremors

Sleepiness

Feeling like you have no energy

17:53–19:23

Narrator: Important Safety Information (continued).

Due to the risk of CRS and neurologic problems, you will receive the following monitoring during treatment with IMDELLTRA^®:

For Day 1 and Day 8 of Cycle 1 doses, your healthcare provider will monitor you for 22 to 24 hours from the start of the IMDELLTRA^® infusion in a
healthcare setting that can manage these side effects.

You should remain within 1 hour of a healthcare setting for a total of 48 hours from the start of the IMDELLTRA^® infusion after your Day 1 and Day
8 of Cycle 1 doses and be accompanied by a caregiver.

For Day 15 of Cycle 1 and Cycle 2 doses, your healthcare provider will watch you for 6 to 8 hours after the IMDELLTRA^® infusion.

For Cycle 3 and Cycle 4 doses, your healthcare provider will watch you for 3 to 4 hours after the IMDELLTRA^® infusion.

For Cycle 5 and later doses, your healthcare provider will watch you for 2 hours after the IMDELLTRA^® infusion.

19:24–20:54

Narrator: Important Safety Information (continued).

Before receiving IMDELLTRA^®, tell your healthcare provider about all of your medical conditions, including if you:

Have an infection

Are pregnant or plan to become pregnant. IMDELLTRA^® may harm your unborn baby.

Females who are able to become pregnant:

Your healthcare provider should do a pregnancy test before you start treatment with IMDELLTRA^®.

You should use an effective form of birth control (contraception) during treatment with IMDELLTRA^®, and for 2 months after the last dose of
IMDELLTRA^®.

Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with IMDELLTRA^®.

Are breastfeeding or plan to breastfeed. It is not known if IMDELLTRA^® passes into your breast milk. Do not breastfeed during treatment with
IMDELLTRA^® and for 2 months after the last dose of IMDELLTRA^®.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal
supplements.

What should I avoid while receiving IMDELLTRA^®?

20:55–22:44

Narrator: Important Safety Information (continued).

What are the possible side effects of IMDELLTRA^®?

IMDELLTRA^® can cause serious side effects, including:

Low white blood cell counts (cytopenia). Decreased blood cell counts can be severe and may include the following:

Low types of white blood cell counts (neutropenia). Low white blood cells can increase your risk for infection.

Low red blood cell counts (anemia). Low red blood cells can cause tiredness and shortness of breath.

Low platelet counts (thrombocytopenia). Low platelet counts can cause bruising or bleeding problems.

22:45–24:14

Narrator: Important safety information (continued).

IMDELLTRA^® can cause serious side effects, including (continued):

The most common side effects of IMDELLTRA^® also include:

Tiredness

Decreased appetite

A bad or metallic taste in your mouth

Fever

Muscle or bone pain

Constipation

Nausea

These are not all the possible side effects of IMDELLTRA^®.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see IMDELLTRA^® full Prescribing Information, including BOXED WARNINGS and Medication Guide on IMDELLTRA.com.

Indications

Get to know IMDELLTRA^® with these patient videos

IMDELLTRA^®: Patient-Doctor Dialogue

IMDELLTRA^®: Dialogue Between Patient-Doctor and Caregiver

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about IMDELLTRA^®?

IMDELLTRA^® can cause side effects that can be severe, life-threatening or cause death, including:

Due to the risk of CRS, you will receive IMDELLTRA^® as per the following “step-up dosing schedule”:

Before receiving IMDELLTRA^®, tell your healthcare provider about all of your medical conditions,
including if you:

Females who are able to become pregnant:

What should I avoid while receiving IMDELLTRA^®?

What are the possible side effects of IMDELLTRA^®?

IMDELLTRA^® can cause serious side effects, including:

What is IMDELLTRA^® (tarlatamab-dlle)?

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about IMDELLTRA^®?

IMDELLTRA^® can cause side effects that can be severe, life-threatening or cause death, including:

You are leaving IMDELLTRA.com

You are leaving IMDELLTRA.com

What are some IMDELLTRA® educational patient videos?

Get to know IMDELLTRA® with these patient videos

IMDELLTRA®: Patient-Doctor Dialogue

IMDELLTRA®: Dialogue Between Patient-Doctor and Caregiver

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about IMDELLTRA®?

IMDELLTRA® can cause side effects that can be severe, life-threatening or cause death, including:

Due to the risk of CRS, you will receive IMDELLTRA® as per the following “step-up dosing schedule”:

Before receiving IMDELLTRA®, tell your healthcare provider about all of your medical conditions, including if you:

Females who are able to become pregnant:

What should I avoid while receiving IMDELLTRA®?

What are the possible side effects of IMDELLTRA®?

IMDELLTRA® can cause serious side effects, including:

What is IMDELLTRA® (tarlatamab-dlle)?

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about IMDELLTRA®?

IMDELLTRA® can cause side effects that can be severe, life-threatening or cause death, including:

What are some IMDELLTRA^®
educational patient videos?

Get to know IMDELLTRA^® with these patient videos

IMDELLTRA^®: Patient-Doctor Dialogue

IMDELLTRA^®: Dialogue Between Patient-Doctor and Caregiver

What is the most important information I should know about IMDELLTRA^®?

IMDELLTRA^® can cause side effects that can be severe, life-threatening or cause death, including:

Due to the risk of CRS, you will receive IMDELLTRA^® as per the following “step-up dosing schedule”:

Before receiving IMDELLTRA^®, tell your healthcare provider about all of your medical conditions,
including if you:

What should I avoid while receiving IMDELLTRA^®?

What are the possible side effects of IMDELLTRA^®?

IMDELLTRA^® can cause serious side effects, including:

What is IMDELLTRA^® (tarlatamab-dlle)?

What is the most important information I should know about IMDELLTRA^®?

IMDELLTRA^® can cause side effects that can be severe, life-threatening or cause death, including: